ArticleJournal of mathematical biology2025
Dynamical modeling and data analysis of HIV infection with infection-age, CTLs immune response and delayed antibody immune response.
Article in Journal of mathematical biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
HIV infection, a leading cause of AIDS, continues to impose a substantial global health burden. This study investigates the mechanisms of HIV infection and immune responses through a delayed infection-age structured model that integrates viral target cell infection, CTLs-mediated immunity, and delayed antibody immune responses. We rigorously analyze the existence, uniqueness, and boundedness of the model's solution semi-flow, followed by detailed examinations of equilibrium states coexistence and local stability. Using clinical HIV case data from Jiangsu Province, we estimate model parameters and assess fitting accuracy. The model successfully replicates key clinical manifestations in four ART-treated patients, underscoring its medical relevance. Our findings suggest that ART efficacy primarily manifests in reduced infection rates and viral release rates. Notably, reverse transcriptase inhibitors, fusion inhibitors, and entry inhibitors demonstrate significantly superior therapeutic efficacy compared to protease inhibitors and treatments targeting drug-resistant viral strains. Moreover, ART exhibits significantly stronger enhancement of cellular immunity (particularly CD8+ T cell responses) than modulation of humoral immunity, viral reservoirs persist despite potent antiretroviral suppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.